Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Managing relapse after CAR-T therapy in ALL

Sara Ghorashian • 12 Jun 2022
EHA 2022
Acute Lymphoblastic Leukemia Leukemia CAR-T

Sara Ghorashian, PhD, MD, FRCP, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, shares some insights into the management of relapse after CAR-T therapy in patients with acute lymphoblastic leukemia (ALL). Dr Ghorashian emphasizes the importance of thorough and systematic data collection and how this data can be used to improve approaches after relapse. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Novartis, UCLB

More from Sara Ghorashian

Exciting updates in ALL and the value of novel immunotherapies
1:11
Exciting updates in ALL and the value of novel immunotherapies
Sara Ghorashian • 11 Dec 2022
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
3:18
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
Sara Ghorashian • 11 Dec 2022
Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
2:18
Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
Sara Ghorashian • 11 Dec 2022
The potential of CAR T-cell therapy in combination with antibodies for the treatment of ALL
2:27
The potential of CAR T-cell therapy in combination with antibodies for the treatment of ALL
Sara Ghorashian • 12 Jun 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals